Kestra Private Wealth Services LLC Purchases 13,331 Shares of Novo Nordisk A/S (NYSE:NVO)

Kestra Private Wealth Services LLC boosted its position in Novo Nordisk A/S (NYSE:NVO) by 37.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 48,640 shares of the company’s stock after acquiring an additional 13,331 shares during the period. Kestra Private Wealth Services LLC’s holdings in Novo Nordisk A/S were worth $4,184,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. International Assets Investment Management LLC lifted its stake in Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after buying an additional 1,796,635 shares during the period. Mediolanum International Funds Ltd acquired a new position in Novo Nordisk A/S in the third quarter valued at about $98,765,000. DAVENPORT & Co LLC lifted its stake in Novo Nordisk A/S by 75.1% in the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after buying an additional 451,641 shares during the period. Wellington Management Group LLP acquired a new position in Novo Nordisk A/S in the third quarter valued at about $42,017,000. Finally, World Investment Advisors LLC lifted its stake in Novo Nordisk A/S by 2,655.9% in the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after buying an additional 270,234 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.9 %

Shares of Novo Nordisk A/S stock opened at $83.90 on Tuesday. The business’s 50 day simple moving average is $91.46 and its 200 day simple moving average is $111.21. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The firm has a market cap of $376.48 billion, a PE ratio of 25.50, a P/E/G ratio of 0.96 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, analysts predict that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 21.88%.

Wall Street Analyst Weigh In

NVO has been the topic of a number of research analyst reports. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.